RNTX - NASDAQ

RT

Rein Therapeutics Inc.

RNTX·NASDAQ

$1.87

+0.53%
HealthcareMedical - Pharmaceuticals

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$52.43M
EPS-1.9600
P/E Ratio-0.96
Earnings Date05/21/2026

rntx

Selling, General and Administrative Expenses

Last Annual Value

10.90M

3-Year CAGR

940%

5-Year CAGR

311%

10-Year CAGR

103%

RT

Rein Therapeutics Inc. Competitors Analysis of Selling, General and Administrative Expenses

RNTX · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
RNTX logo
Rein Therapeutics Inc.
NASDAQ:RNTX
10.90M
886.5%308.4%N/A 
ATNM logo
Actinium Pharmaceuticals, Inc.
AMEX:ATNM
12.08M
-3.2%8.4%2.7%
BCAB logo
BioAtla, Inc.
NASDAQ:BCAB
21.85M
-5.6%-10.7%N/A
BEAT logo
HeartBeam, Inc.
NASDAQ:BEAT
7.69M
-3.3%30.5%-21.4%
KZR logo
Kezar Life Sciences, Inc.
NASDAQ:KZR
18.51M
-11.3%3.3%27.6%
MRSN logo
Mersana Therapeutics, Inc.
NASDAQ:MRSN
40.81M
-11.8%2.0%19.3%
RT

Rein Therapeutics Inc. Fair Value Envelope

RNTX · NASDAQ

Our analysis suggests that RNTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.87, this represents a potential HIDDEN relative to our calculated worth for Rein Therapeutics Inc..

HIDDEN
Intrinsic Value
Current Price: $1.87

Related Guides

Blog Categories

Continue your RNTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.